In Europe, the sector of plants used for therapeutic and industrial purposes is entering a phase of accelerated clarification. For professionals in hemp, CBD, and derivative products, 2026 confirms a fundamental trend: market access no longer depends solely on the legality of cultivation, but also on the ability to meet increasingly stringent safety, traceability, and compliance regulations. Beyond the THC thresholds, several regulatory entry points are actually being redefined.
For adult consumers in France and the European Union, this development is rather good news. It can make the market more transparent, better regulated, and safer, provided they understand that there isn't a single framework but rather several levels: agriculture, food, and medicine. It is precisely at the intersection of these three levels that European regulations for therapeutic and industrial hemp.
A three-speed European framework
The first key to understanding European regulations for therapeutic and industrial hempis recognizing that they are based on three distinct legal frameworks. First, there is agriculture, with its cultivation rules, authorized varieties, and eligibility for subsidies. Then comes food, with its food safety requirements, contaminants, and thresholds applicable to products intended for consumption. Finally, there is medicine, which is subject to even stricter standards regarding authorization, manufacturing, and distribution.
This framework explains why a product or raw material can be perfectly legal at one level but subject to additional constraints at another. A legally cultivated hemp plant does not automatically become a food product freely available for distribution without further examination. Similarly, a wellness or technical use does not automatically grant access to a recognized therapeutic use within the medical system.
In practice, the European sector therefore navigates between these three regulatory levels: agriculture for THC thresholds and the Common Agricultural Policy (CAP), food for infusions and contaminants, and pharmaceuticals for therapeutic preparations and clinical requirements. For reputable brands and discerning consumers, this framework makes it easier to distinguish a compliant product from one that is simply presented as such.
The agricultural threshold of 0.3% remains the basis for cultivation
From an agricultural perspective, the foundation remains very clear: Regulation (EU) 2021/2115 maintains the 0.3% tetrahydrocannabinol threshold for hemp hectares to be eligible for CAP subsidies. In other words, industrial hemp cultivation continues to operate within a framework of regulated and controlled varieties, with a key numerical benchmark for accessing public support.
This threshold should not be confused with the limits applicable to finished products. The 0.3% primarily concerns the plant in the field and the agricultural eligibility requirements, not all hemp-derived goods. This is a crucial distinction, often misunderstood, yet it structures the entire chain, from seed to marketed product.
UEDA also points out that the cultivation of industrial hemp is legal under strict conditions and that a member state cannot prohibit it when it complies with the requirements of EU law, in accordance with the case law of the CJEU. For producers, this is an important signal: Europe recognizes the legitimacy of the sector, but within a precise and documented technical framework.
Brussels is easing some controls, but not abandoning surveillance
In 2026, Brussels also sent a message of administrative simplification. Delegated Regulation (EU) 2026/177 amends certain CAP rules to offer Member States greater flexibility regarding verification deadlines and allow for a reduction in certain inspection rates, with the aim of lowering administrative costs. For farmers, this is a welcome development in a sector where compliance can quickly become burdensome and expensive.
But this easing of regulations does not mean the end of inspections. EU law maintains, in certain situations, a minimum of 15% on-site inspections for hemp cultivation areas. This requirement clearly reflects the current European philosophy: simplify where possible, and monitor where regulatory and health risks remain significant.
The sector must therefore contend with a dual trend. On the one hand, less procedural rigidity on certain points. On the other, continued vigilance regarding crops, acreage, and the actual compliance of farms. For reputable players, this evolution can be positive, as it fosters a more fluid market while limiting abuses that undermine the sector's credibility.
The new rules on infusions mark a turning point
One of the most significant changes concerns hemp leaves intended for infusion. Regulation (EU) 2026/1828 of 28 July 2026 introduces new maximum levels of Δ9-THC for hemp leaves used in infusions as well as for ready-to-drink infusions. Its entry into force comes 20 days after publication, reflecting a commitment to swift implementation.
This measure is strategic for a significant portion of the market. Infusions occupy a unique space at the intersection of botanical tradition, well-being, and food safety. By setting explicit thresholds, the European Union is not closing the door to these products; rather, it seeks to provide them with a more stable framework, with harmonized benchmarks for operators and regulatory authorities.
The Commission clearly links this development to an objective of “high level of human health protection”. This point is fundamental: the thresholds are not merely tools of economic policing; they are becoming instruments of public health. For consumers, this means that compliance should not be seen as a mere formality, but as a genuine criterion of safety.
Food: Hemp is now fully addressed as a health issue
The movement isn't limited to infusions. Maximum THC levels in several hemp-based products have already been harmonized across Europe. The Commission has set limits of 3.0 mg/kg for hemp seeds, 7.5 mg/kg for hemp seed oil, and 3 mg/kg for other products . These standards demonstrate that the hemp food market is no longer operating in a legal gray area.
Another key element: European regulations on food contaminants explicitly include Δ9-THC among the monitored plant toxins. This is a strong regulatory signal. Hemp is no longer seen simply as a promising agricultural crop or a versatile raw material; it is also assessed as a potential source of exposure, which necessitates a much more rigorous analytical approach.
At the same time, the EU considers hemp leaf infusions not to be “novel foods” when they do not contain the flowering and fruiting tops. This facilitates the marketing of certain products, but under strict health controls. In short, access can be simplified administratively, while remaining stringent regarding composition, thresholds, and the safety of the final product.
Therapeutic uses: access still highly dependent on Member States
When moving from industrial hemp to therapeutic uses, the level of requirements changes immediately. Access to medical cannabis still largely depends on individual Member States. The UEDA points out that, in the absence of a general central authorization, some countries rely on the exception provided for in Article 5 of Directive 2001/83/EC to allow certain cannabis-based preparations.
This reality creates a Europe with varying levels of access. Depending on the country,therapeutic access may involve compounded preparations, specific programs, products authorized within a narrow framework, or highly regulated hospital circuits. For both patients and healthcare providers, this means that free movement is not automatic once one enters the realm of pharmaceuticals.
The medical sector is also subject to particularly stringent manufacturing, distribution, and safety requirements. Quality standards such as GMP, document validation, pharmacovigilance, and clinical oversight clearly distinguish this segment from the wellness or food markets. The EMA's June 2026 monthly report, with its thousands of ongoing and completed procedures for human medicines, serves as a reminder of the extent to which the European pharmaceutical supply chain relies on a dense and structured regulatory framework.
CBD and new cannabinoids: enhanced monitoring
CBD remains central to the commercial development of the sector, as well as to the attention of regulators. EUDA's EDR 2026 highlights that certain cannabinoid substances are often produced from CBD extracted from hemp with low THC content. This observation automatically places derived products under increased scrutiny, especially when innovation outpaces legal harmonization.
For consumers, this doesn't mean that all new cannabinoids are inherently prohibited or problematic. Rather, it serves as a reminder to prioritize products that have been laboratory-tested, with clear traceability, accessible analyses, and honest statements about their status. In a rapidly evolving market, transparency becomes a major competitive advantage.
For CBD professionals, the challenge is twofold: remaining competitive while anticipating regulatory requirements. Product safety, residue control, accurate identification of cannabinoids present, and documentation compliance are now as important as price, aroma, or novelty. This represents a fundamental transformation of the European market.
Why is Europe now tightening the framework
The relative tightening of the regulations is not without reason. EUDA estimates that 24.9 million European adults have used cannabis. With such a large user base, political and health pressure is inevitable. European institutions are therefore seeking to more clearly distinguish between legal channels, controlled uses, and products safe enough to be offered to consumers.
At the same time, cannabis regulatory models are evolving rapidly in several Member States. The 2026 European Drug Regulation (EDR) notes the development of approaches integrating prevention, non-profit sales, and monitoring and evaluation. This national diversification is pushing Europe to better define the boundaries between agriculture, food, well-being, therapeutics, and substance control.
The legislative discussions of 2026 also demonstrate that hemp has become a genuine agricultural and market policy issue, including in proposals concerning the common organization of markets. In other words, it is no longer simply considered a marginal or alternative crop. Hemp is now an economic, health, and strategic issue at the European level.
What this changes in concrete terms for the industry and for consumers
For producers and sellers, the new European regulations require a much more nuanced understanding of product categories. Agricultural raw materials are not sold in the same way as herbal teas, cooking oils, CBD-rich extracts, or therapeutic preparations. Each segment has its own rules, thresholds, compliance requirements, and specific risks.
For buyers, this clarification is helpful. It allows them to better understand why the most reputable products come with analyses, precise information about their composition, and careful guidance on their uses. A mature market isn't just about more choice; it's also about greater guarantees regarding the origin, legality, and safety of the products offered.
Ultimately, European regulations for therapeutic and industrial hemp don't close the market; they professionalize it. Operators capable of combining quality, compliance, and accessibility stand to gain significantly from this context. And for adult consumers seeking legal, tested products that comply with European law, this framework can sustainably strengthen trust.
Europe is therefore reshaping the sector around a simple principle: access is possible, but it must be transparent, controlled, and compatible with the protection of public health. Between the 0.3% agricultural threshold, the new limits for infusions, harmonized food regulations, and the requirements of the medical supply chain, the sector is moving towards a clearer structuring of its various uses.
For hemp and CBD stakeholders, the message is clear: the future belongs to supply chains that can prove what they sell, how they produce it, and under what framework they market it. In a more technical but also more stable European environment, compliance is no longer an obstacle; it is becoming a true driver of trust, sustainability, and market access.
